Global Restless Legs Syndrome Market 2015-2019
RLS is a neurological disease; it is also known as Willis-Ekbom disease. People with RLS experience an overwhelming desire to move their legs. It leads to an unpleasant pain in the limbs, leading to a disturbance in sleep pattern of patients. The condition aggravates at night or when the person is at rest. It occurs in both genders, but higher prevalence is seen in women than men. It affects people of all ages but mostly affecting the middle-aged and elderly people. Its common symptoms are uncomfortable itching pain in the legs, leading to a disruption in the sleep pattern and ultimately affecting the quality of life of individuals. The precise cause of RLS is not known but with the extensive investigations done in the field, it is believed to be due to predisposing genetic factors or due to low levels of iron in the brain or due to the disturbances in the dopaminergic balance. Till date, there is no specific cure for the disorder. The drugs present in the market help in the symptomatic treatment of the disorder and in relieving the uneasiness caused due to this disorder.
Technavio's analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.
Covered in this report
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
Technavio's report, the Global RLS Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and APAC and EMEA; it also covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Restless Legs Syndrome Market 2015-2019
Technavio recognizes the following companies as the key players in the gobal restless legs syndrome market: Boehringer Ingelheim, GlaxoSmithKline, UCB and XenoPort
Other Prominent Vendors in the market are: Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva Neuroscience
Commenting on the report, an analyst from Technavio’s team said: “The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.”
According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.
Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market.
Boehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics and Teva NeuroscienceBoehringer Ingelheim, GlaxoSmithKline, UCB, XenoPort, Alexza Pharmaceuticals, Astellas Pharma, Axxonis Pharma, Bayer Healthcare, Impax Pharmaceuticals, Luitpold Pharmaceuticals, Merz Pharmaceuticals, Mundipharma, Newron Pharmaceuticals, Serina Therapeutics, Teva Neuroscience
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook